- Home
- LTRN vs XLO Comparison
LTRN vs XLO Comparison
Compare LTRN & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRN
- XLO
- Stock Information
- Founded
- LTRN 2013
- XLO 2016
- Country
- LTRN United States
- XLO United States
- Employees
- LTRN N/A
- XLO N/A
- Industry
- LTRN Biotechnology: Pharmaceutical Preparations
- XLO Biotechnology: Pharmaceutical Preparations
- Sector
- LTRN Health Care
- XLO Health Care
- Exchange
- LTRN Nasdaq
- XLO Nasdaq
- Market Cap
- LTRN 49.9M
- XLO 41.8M
- IPO Year
- LTRN 2020
- XLO 2021
- Fundamental
- Price
- LTRN $3.80
- XLO $0.75
- Analyst Decision
- LTRN Strong Buy
- XLO Buy
- Analyst Count
- LTRN 1
- XLO 1
- Target Price
- LTRN $25.00
- XLO $2.00
- AVG Volume (30 Days)
- LTRN 73.1K
- XLO 944.4K
- Earning Date
- LTRN 11-12-2025
- XLO 11-13-2025
- Dividend Yield
- LTRN N/A
- XLO N/A
- EPS Growth
- LTRN N/A
- XLO N/A
- EPS
- LTRN N/A
- XLO N/A
- Revenue
- LTRN N/A
- XLO $31,804,000.00
- Revenue This Year
- LTRN N/A
- XLO $519.70
- Revenue Next Year
- LTRN N/A
- XLO $44.57
- P/E Ratio
- LTRN N/A
- XLO N/A
- Revenue Growth
- LTRN N/A
- XLO 588.40
- 52 Week Low
- LTRN $2.55
- XLO $0.62
- 52 Week High
- LTRN $6.12
- XLO $1.70
- Technical
- Relative Strength Index (RSI)
- LTRN 55.43
- XLO 46.94
- Support Level
- LTRN $2.86
- XLO $0.73
- Resistance Level
- LTRN $3.42
- XLO $0.81
- Average True Range (ATR)
- LTRN 0.28
- XLO 0.06
- MACD
- LTRN 0.03
- XLO -0.00
- Stochastic Oscillator
- LTRN 99.80
- XLO 52.16
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.